Results 41 to 50 of about 4,852 (207)

Tenofovir-Containing Antiretroviral Therapy and Clinical Outcomes of SARS-CoV-2 Infection in People Living with HIV

Viruses, 2023
Tenofovir has been hypothesized to be effective against COVID-19 and is available as two prodrugs, tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF), both part of antiretroviral therapy (ART) regimens.
María F. Rombini, Diego Cecchini, Sofía Diana Menendez, Liliana Calanni, Rosana Cuini, Elena Obieta, María M. Greco, Fabricio Morales, Laura Morganti, Claudia Migazzi, Yasmin El Kozah, Pablo Parenti, Isabel Cassetti, on behalf of the COVIDARE Study Team   +13 more
doaj   +1 more source

The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV‐Infected Persons [PDF]

Clinical Pharmacology & Therapeutics, 2020
The secondary lymphoid tissues (LT), lymph nodes (LN) and gut‐associated lymphoid tissue are the primary sites of HIV replication and where the latent pool of virus is maintained. We compared the pharmacokinetics of tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) in LT of 13 HIV‐infected persons receiving a TDF‐containing ...
Courtney V. Fletcher, Anthony T. Podany, Ann Thorkelson, Lee C. Winchester, Timothy Mykris, Jodi Anderson, Siri Jorstad, Jason V. Baker, Timothy W. Schacker   +8 more
openaire   +2 more sources

Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials

International Journal of Infectious Diseases, 2020
Background: Tenofovir disoproxil fumarate (TDF) can cause renal and bone toxicity, which is associated with high plasma tenofovir concentrations in antiretroviral treatment of HIV-1 infected patients.
Xingbao Tao, Yanqiu Lu, Yihong Zhou, Lvlang Zhang, Yaokai Chen   +4 more
doaj   +1 more source

Impact of Combination Antiretroviral Treatment on Liver Metabolic Health in HIV-Infected Persons

Viruses, 2023
In the last three decades, there has been a considerable improvement in human immunodeficiency virus (HIV) therapy. Acquired immunodeficiency syndrome (AIDS) is no longer a common cause of death for people living with HIV (PLWH) in developed countries ...
Michał Biały, Marcin Czarnecki, Małgorzata Inglot   +2 more
doaj   +1 more source

Fanconi Syndrome Due to Tenofovir Disoproxil Fumarate in a Patient with Chronic Hepatitis B Induced Cirrhosis: A Case Report

Case Reports in Clinical Practice
We present a 63-year-old woman with chronic hepatitis B. The patient has a history of cirrhosis due to chronic hepatitis B and is under treatment with Tenofovir disoproxil fumarate.
Milad Khodabakhshi, Behshad Pazooki
doaj   +1 more source

Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV

Journal of Renal and Hepatic Disorders, 2018
Tenofovir disoproxil fumarate (TDF) is a common antiretroviral utilised in the treatment of human immunodeficiency virus (HIV) and hepatitis B infections.
Nicole Marie Lioufas, Alan Street, Paul Champion de Crespigny, Stephen G Holt   +3 more
doaj   +1 more source

Compare HBV relapse rates in patients who discontinue tenofovir disoproxil fumarate or tenofovir alafenamide fumarate

, 2022
Abstract Background/purpose: Clinical relapse occurred majorly within the first six months after stopping tenofovir disoproxil fumarate (TDF) in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients. However, the incidence and relapse pattern in patients stopping Tenofovir alafenamide fumarate (TAF), a prodrug of tenofovir ...
CH Chen, Wen-Juei Jeng, Tsung-Hui Hu, Yen-Chun Liu, Jing-Houng Wang, Chao-Hung Hung, Sheng-Nan Lu, Rong-Nan Chien   +7 more
openaire   +1 more source

4CPS-060 Prescription analysis of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in a third level hospital [PDF]

Section 4: Clinical Pharmacy Services, 2020
Background and importance Tenofovir alafenamide (TAF) is a novel tenofovir prodrug, recently entering the market for HIV infections. TAF results in higher intracellular concentrations of the active metabolite tenofovir diphosphate compared with tenofovir disoproxil fumarate (TDF), allowing for much lower doses of TAF versus TDF.
A Caraffa, A Colicchio, L Gasperoni, G Selvetti, I Tommasini, E Zuccarini, M Mancini   +6 more
openaire   +1 more source

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate in a cohort of patients with HBV infection: A retrospective study

Journal of Clinical Virology Plus
Background: Tenofovir disoproxil fumarate (TDF) as first-line therapy for chronic HBV infection is related to nephrotoxicity. Tenofovir alafenamide fumarate (TAF) has been approved with a similar virological and serological response, but lower toxicity ...
Giacomo Stroffolini, Valentina Dodaro, Amedeo De Nicolò, Jessica Cusato, Giovanni Di Perri, Antonio D'Avolio, Lucio Boglione   +6 more
doaj   +1 more source

Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression

Alimentary Pharmacology &Therapeutics, EarlyView.
Serum HBV RNA levels at viral suppression predict HCC development in nucleos(t)ide analogue‐treated patients with chronic hepatitis B, outperforming Hepatitis B core‐related antigen alone. ABSTRACT Background Despite achieving undetectable hepatitis B virus (HBV) DNA levels with nucleos(t)ide analogue (NA) therapy, patients with chronic hepatitis B ...
Takashi Kumada, Hidenori Toyoda, Satoshi Yasuda, Yuichi Koshiyama, Takanori Ito, Tomoyuki Akita, Junko Tanaka   +6 more
wiley   +1 more source